A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 4, 2014, Pages 316-322

  Marchetti, Carlo ^a,b   Chojnacki, Jeremy ^c   Toldo, Stefano ^a   Mezzaroma, Eleonora ^a   Tranchida, Nicla ^a   Rose, Scott W ^a   Federici, Massimo ^b   Van Tassell, Benjamin W ^a   Zhang, Shijun ^b   Abbate, Antonio ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Department of Systems Medicine University of Rome Tor Vergata ^*  (United States)

Author keywords

Acute myocardial infarction; caspase 1; inflammasome

Indexed keywords

16673 34 0; 5 CHLORO 2 METHOXY N [2 (4 SULFAMOYLPHENYL) ETHYL] BENZAMIDE; ADENOSINE TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; CRYOPYRIN; GLIBENCLAMIDE; GLUCOSE; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; PROTEIN INHIBITOR; TROPONIN I; UNCLASSIFIED DRUG; 5-CHLORO-2-METHOXY-N-(2-(4-SULFAMOYLPHENYL)ETHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONAMIDE;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; GLUCOSE METABOLISM; HEART INFARCTION SIZE; HEART MUSCLE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MACROPHAGE; MALE; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PERITONITIS; SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; BLOOD GLUCOSE; CARRIER PROTEINS; CELL LINE; INFLAMMASOMES; MACROPHAGES; MALE; MICE; MYOCARDIAL REPERFUSION INJURY; PERITONITIS; SULFONAMIDES;

EID: 84898599015     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000053     Document Type: Article

References (18)

1. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159-173.
2. Strowig T, Henao-Mejia J, Elinav E, et al. Inflammasomes in health and disease. Nature. 2012;481:278-286.
3. Mezzaroma E, Toldo S, Farkas D, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA. 2011;108:19725-19730.
4. Toldo S, Mezzaroma E, Abbate A. Interleukin-1 blockade in acute myo-cardial infarction and heart failure: ready for clinical translation? Transl Med. 2013;3:e114.
5. Wilson SP, Cassel SL. Inflammasome-mediated autoinflammatory disorders. Postgrad Med. 2010;122:125-133.
6. Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cry-opyrin/NALP3 inflammasome. J Cell Biol. 2009;187:61-70.
7. Claycomb WC, Lanson NA Jr, Stallworth BS, et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA. 1998;95:2979-2984.
8. Toldo S, Seropian IM, Mezzaroma E, et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2011;51:244-251.
9. Kumar H, Kumagai Y, Tsuchida T, et al. Involvement of the NLRP3 inflammasome in innate and humoral adaptive immune responses to fungal beta-glucan. J Immunol. 2009;183:8061-8067
10. Sandanger Ø, Ranheim T, Vinge LE, et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2013;99:164-174.
11. Mezzaroma E, Toldo S, Abbate A. Role of NLRP3 (cryopyrin) in acute myocardial infarction. Cardiovasc Res. 2013;99:225-226.
12. Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123:594-604.
13. Merkle S, Frantz S, Schön MP, et al. A role for caspase-1 in heart failure. Circ Res. 2007;100:645-653.
14. Van Tassell BW, Toldo S, Mezzaroma E, et al. Targeting interleukin-1 in heart disease. Circulation. 2013;128:1910-1923.
15. Abbate A, Kontos MC, Grizzard JD, et al; VCU-ART Investigators. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010;105:1371-1377.
16. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111:1394-1400.
17. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633-652.
18. López-Castejón G, Pelegrín P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs. 2012;21:995-1007.